X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
IHL-675A is a fixed dose combination of cannabidiol and hydroxychloroquine. It is being investigated for rheumatoid arthritis, inflammatory bowel disease and lung inflammation.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination,synergistically to inhibit production of key inflammatory cytokines.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
Codebase Ventures provided an update on the continued development of its proposed transdermal delivery technology for hydroxychloroquine (HCQ). The drug has been approved by the USFDA as a treatment against malaria, lupus, and rheumatoid arthritis.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
The Phase 2 study reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol including nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.
Lead Product(s): Nicotinamide Riboside,Hydroxychloroquine Sulphate,Serine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Niagen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within ACOVACT, different treatments for COVID-19 are compared to one another. The trial will evaluate Fas ligand blocker asunercept.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apogenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
Rafael Pharmaceuticals will initiate a Phase 2 clinical trial of CPI-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue, in partnership with Sara’s Cure and Sarcoma Alliance for Research through Collaboration (SARC).
Lead Product(s): Devimistat,Hydroxychloroquine Sulphate
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sara’s Cure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 01, 2020
Details:
The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir with a loaded dose and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.
Lead Product(s): Lopinavir,Ritonavir,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Inserm-ANRS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
The finding suggest that hydroxychloroquine is not effective for the treatment of COVID-19 was consistent across patient subgroups and for all evaluated outcomes, including clinical status, mortality, organ failures, duration of oxygen use, and hospital length of stay.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The manuscript describes how inhalable liposomal hydroxychloroquine (TLC19) may provide clinical benefit and serve as a potential treatment for COVID-19 has been peer-reviewed and accepted by Clinical and Translational Science (CTS) journal.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: TLC19
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
Devimistat is designed to target the mitochondrial tricarboxylic acid cycle, a process essential to tumor cell multiplication and survival, selectively in cancer cells and substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents.
Lead Product(s): Devimistat,Hydroxychloroquine Sulphate
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Interim data from the WHO-coordinated Solidarity Therapeutics Trial suggest that remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon regimens in COVID patients have little or no impact on 28-day mortality or the in-hospital course of COVID-19.
Lead Product(s): Remdesivir,Lopinavir,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: World Health Organization
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
In preclinical studies, TLC19 demonstrated 30-fold exposure in the lungs while achieving lower blood and heart exposure than oral HCQ and unformulated HCQ.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: TLC19
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
The Phase I randomized, vehicle-controlled, blinded study will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of inhaled TLC19 in 30 healthy volunteers.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: TLC19
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
The Phase 2 study reported patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time when receiving the standard of care in combination with a nutritional protocol including nicotinamide riboside (NR).
Lead Product(s): Nicotinamide Riboside,Hydroxychloroquine Sulphate,Serine
Therapeutic Area: Infections and Infectious Diseases Product Name: Niagen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
TLC19 utilizes TLC’s existing proprietary liposome technology to encapsulate ~1/100 of the oral HCQ dose into an inhalable formulation for direct deposit into the airways and lungs.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: TLC19
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2020
Details:
The manuscript compared equivalent doses of inhalable liposomal HCQ to IV unformulated HCQ in which inhalable liposomal HCQ achieved increased exposure and half-life in the lungs while also achieving lower blood and heart exposure.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
Italian clinical study finds combined strains of live bacteria reduced diarrhea and lessened progression of symptoms in hospitalized COVID-19 patients.
Lead Product(s): Live Biotherapeutic Product,Hydroxychloroquine Sulphate,Antibiotics
Therapeutic Area: Infections and Infectious Diseases Product Name: SivoBiome
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
WHO accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2020
Details:
A data and safety monitoring board determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19. After its fourth interim analysis the DSMB recommended to the NHLBI, part of NIH, to stop the study.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: JWT629
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020
Details:
The COVID SHIELD clinical study will test an expanded indication for generic Hydroxychloroquine (HCQ) as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Walter and Eliza Hall Institute of Medical Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 20, 2020
Details:
The clinical trial protocol will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection.
Lead Product(s): Hydroxychloroquine Sulphate,Azithromycin,Ascorbic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
The AIDS Clinical Trials Group (ACTG) has launched ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2).
Lead Product(s): Hydroxychloroquine Sulphate,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Led by the University of Oxford, the PRINCIPLE trial aims to prevent the development of more serious coronavirus symptoms in the patient population. It will assess the drugs’ ability to slow or halt the disease progression and prevent hospital admission.
Lead Product(s): Hydroxychloroquine Sulphate,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
The findings showed that patients on hydroxychloroquine had the same risk of intubation or death as those who were not treated with the drug.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
Company's to donate Hydroxychloroquine tablets to support a Phase 2 clinical trial exploring hydroxychloroquine as preventive treatment for COVID-19 in patients with cancer under radiation therapy.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Researchers at The Lundquist Institute began a clinical trial designed to find out whether hydroxychloroquine and azithromycin reduce hospitalization and/or death in people suffering from COVID-19.
Lead Product(s): Azithromycin,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Clinical trial of immunomodulators combining Imiquimod and Hydroxychloroquine to prevent and treat early COVID-19 infection.
Lead Product(s): Imiquimod,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
The new clinical trial will test antimalarial drug hydroxychloroquine, anti-HIV drug lopinavir/ritonavir in patients who were in close contact with newly confirmed COVID-19 cases.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
The AustralaSian COVID-19 Trial is attempting to see if already established treatments might prove effective against COVID-19 which as a ‘new disease’ has no current treatments.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
The drug hydroxychloroquine has garnered interest in the medical community after showing preliminary promise in small clinical studies, including one with co-administration with the antibiotic azithromycin.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: JWT629
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Opaganib was administered in addition to standard-of-care, including hydroxychloroquine background therapy, and was well tolerated.
Lead Product(s): Opaganib,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Details:
A trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with COVID-19 has begun, with the first participants now enrolled in Tennessee.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
Details:
Results from these studies will help us to understand the value of hydroxychloroquine in treatment of COVID-19.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
Details:
The study in collaboration with Lupus Therapeutics' Lupus Clinical Investigators Network (LuCIN), will assess the potential benefit of hydroxychloroquine in lupus COVID-19 patients.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
Details:
Researchers at Rutgers Cancer Institute are exploring if azithromycin combined with hydroxychloroquine is better than hydroxychloroquine alone for treatment of patients with COVID-19.
Lead Product(s): Azithromycin,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020
Details:
The program will engage the powerful PCORI-funded PCORnet®, the National Patient-Centered Clinical Research Network, to evaluate hydroxychloroquine as a preventive drug for the novel coronavirus.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PCORI
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 02, 2020
Details:
Company reports potent synergy between its fibroblast-based cell therapy and hydroxychloroquine .
Lead Product(s): Fibroblast cells,Hydroxychloroquine Sulphate,Peptides
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
Rising Pharmaceuticals and its partner Laurus will supply hydroxychloroquine to support University of Minnesota's study on hydroxychloroquine as a treatment of COVID-19.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rising Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 27, 2020
Details:
Recruitment initiated in 2nd arm of Phase 1/2a study evaluating opaganib in combination with hydroxychloroquine in advanced cholangiocarcinoma.
Lead Product(s): Opaganib,Upamostat,Hydroxychloroquine Sulphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
